| scholarly article | Q13442814 |
| P2093 | author name string | Snorri S Thorgeirsson | |
| Anthony J Scarzello | |||
| Jesper B Andersen | |||
| Jimmy K Stauffer | |||
| Jonathan M Weiss | |||
| Rachel L De Kluyver | |||
| Robert H Wiltrout | |||
| Timothy C Back | |||
| P2860 | cites work | Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis | Q27478444 |
| Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression | Q29615766 | ||
| EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features | Q30493364 | ||
| Genome-wide mRNA expression analysis of hepatic adaptation to high-fat diets reveals switch from an inflammatory to steatotic transcriptional program | Q33493427 | ||
| Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis | Q33623036 | ||
| Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies | Q33636256 | ||
| A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases | Q33789567 | ||
| Cancer gene discovery in hepatocellular carcinoma | Q34002120 | ||
| Progenitor-derived hepatocellular carcinoma model in the rat. | Q34037698 | ||
| Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. | Q34114761 | ||
| beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. | Q34302259 | ||
| Experimental models of hepatocellular carcinoma | Q34345987 | ||
| Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas | Q34380511 | ||
| Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype | Q34619635 | ||
| Distinct pathways of genomic progression to benign and malignant tumors of the liver. | Q35970966 | ||
| Induction of ovarian cancer by defined multiple genetic changes in a mouse model system | Q36496578 | ||
| Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease | Q36820197 | ||
| Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis | Q37065772 | ||
| Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. | Q37132646 | ||
| The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications | Q37160617 | ||
| PTEN at the crossroad of metabolic diseases and cancer in the liver. | Q37261338 | ||
| Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. | Q37298654 | ||
| Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma | Q37696402 | ||
| A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver | Q39988585 | ||
| EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma | Q40006245 | ||
| Subtype classification of hepatocellular adenoma | Q43112827 | ||
| Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement | Q44666331 | ||
| Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer | Q46520772 | ||
| Body size and risk of epithelial ovarian and related cancers: a population-based case-control study | Q47235553 | ||
| Prognostic significance of beta-catenin nuclear expression in hepatocellular carcinoma | Q47236438 | ||
| Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. | Q52087746 | ||
| Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. | Q53341563 | ||
| Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. | Q54443542 | ||
| Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer | Q62112715 | ||
| IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells | Q73289660 | ||
| Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin | Q73735409 | ||
| Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma | Q81128776 | ||
| Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma | Q81329832 | ||
| Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors | Q82499265 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2718-27 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors | |
| P478 | volume | 71 |
| Q35990259 | A multi-mineral natural product inhibits liver tumor formation in C57BL/6 mice. |
| Q59790534 | A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment |
| Q28079789 | Aberrant regulation of Wnt signaling in hepatocellular carcinoma |
| Q59791348 | An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma |
| Q27310334 | An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis |
| Q36055039 | Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections |
| Q59358386 | Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs |
| Q38349665 | Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches |
| Q35916968 | Defining the critical hurdles in cancer immunotherapy |
| Q38853191 | Delivery strategies and potential targets for siRNA in major cancer types |
| Q92341122 | Efficient nanocarriers of siRNA therapeutics for cancer treatment |
| Q41466023 | FAK Kinase Activity Is Required for the Progression of c-MET/β-Catenin-Driven Hepataocellular Carcinoma |
| Q34791002 | FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis |
| Q47850258 | FOXO3, estrogen receptor alpha, and androgen receptor impact tumor growth rate and infiltration of dendritic cell subsets differentially between male and female mice |
| Q91873968 | Focal Adhesion Kinase and β-Catenin Cooperate to Induce Hepatocellular Carcinoma |
| Q36415111 | Functional consequences of WNT3/Frizzled7-mediated signaling in non-transformed hepatic cells |
| Q38183539 | Hydrodynamic transfection for generation of novel mouse models for liver cancer research |
| Q38107461 | Inflammation and liver tumorigenesis |
| Q54976722 | Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. |
| Q37282535 | LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours |
| Q34185231 | Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse |
| Q41847265 | Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice. |
| Q49165832 | Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activation |
| Q36922108 | Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype |
| Q94521075 | Oncogenic driver genes and tumor microenvironment determine the type of liver cancer |
| Q38089341 | Pharmacological modulation of beta-catenin and its applications in cancer therapy |
| Q50284721 | Prognostic significance of c-Met, β-catenin and FAK in patients with hepatocellular carcinoma following surgery |
| Q64097554 | Promotion of growth factor signaling as a critical function of β-catenin during HCC progression |
| Q50986588 | Protein disulfide isomerase a4 acts as a novel regulator of cancer growth through the procaspase pathway |
| Q35273519 | SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice |
| Q36190850 | Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy |
| Q35631841 | Stem cells in liver diseases and cancer: recent advances on the path to new therapies |
| Q98946917 | Study on the hepatocellular carcinoma model with metastasis |
| Q38556534 | Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy |
| Q34539365 | c-Myc and transforming growth factor α enhance the development of hepatic lesions due to mutant β-catenin in transgenic mice |
| Q38993024 | β-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma |
Search more.